文献速递妇科

铂类化疗期间抗生素治疗对晚期上皮性卵巢癌女性生存和复发的影响

Impact of antibiotic treatment during platinum chemotherapy on survival and recurrence in women with advanced epithelial ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2020-09-17

该回顾性单中心队列研究纳入2009至2015年接受肿瘤细胞减灭术和铂类化疗的424例新诊断III/IV期上皮性卵巢癌女性,分析化疗期间抗生素治疗(ABX)对无进展生存期(PFS)和总生存期(OS)的影响。结果显示,ABX与PFS和OS降低相关,抗革兰阳性菌抗生素(anti-G+ABX)同样与PFS和OS降低相关,多变量分析中关联仍显著。作者结论认为ABX治疗与晚期上皮性卵巢癌铂类化疗患者PFS和OS降低相关,需机制研究探究ABX对铂类化疗反应的负面影响。

要点

  • 化疗期间ABX与更差PFS相关(17.4 vs 23.1个月,HR 1.50,95%CI 1.20-1.88,p<0.001)。
  • 化疗期间ABX与更差OS相关(45.6 vs 62.4个月,HR 1.63,95%CI 1.27-2.08,p<0.001)。
  • anti-G+ABX与更差PFS和OS相关,多变量分析中关联仍显著。

核心结论

  • 在这项接受铂类化疗的晚期上皮性卵巢癌女性的回顾性队列研究中,ABX治疗与PFS和OS降低相关。
  • 需机制研究探究ABX对上皮性卵巢癌铂类化疗反应的负面影响。

研究设计与样本

  • 回顾性单中心队列研究,纳入2009至2015年新诊断III/IV期上皮性卵巢癌女性(n=424),均接受肿瘤细胞减灭术和铂类化疗。
  • 记录ABX使用超过48小时,包括抗革兰阳性菌抗生素(anti-G+ABX)。
  • 采用单变量和多变量Cox回归模型评估ABX对PFS和OS的影响。

主要发现

  • 424例合格女性中,34.7%(n=147)接受ABX,11.3%(n=48)接受anti-G+ABX。
  • ABX组对比无ABX组:PFS 17.4 vs 23.1个月(HR 1.50,95%CI 1.20-1.88,p<0.001),OS 45.6 vs 62.4个月(HR 1.63,95%CI 1.27-2.08,p<0.001)。
  • anti-G+ABX组对比无ABX组:PFS 16.5 vs 23.1个月(HR 1.85,95%CI 1.33-2.55),OS 35.0 vs 62.4个月(HR 2.12,95%CI 1.50-3.0,p<0.001)。
  • 多变量分析:所有ABX与PFS恶化相关(HR 1.31,95%CI 1.04-1.65,p=0.02),anti-G+ABX与PFS恶化相关(HR 1.50,95%CI 1.07-2.10,p=0.02);所有ABX与OS恶化相关(HR 1.52,95%CI 1.18-1.96,p=0.001),anti-G+ABX与OS恶化相关(HR 1.83,95%CI 1.27-2.62,p=0.001)。
  • Clavien Dindo评分升高与PFS恶化相关(1-2级:HR 1.52,95%CI 1.14-2.03,p=0.004;3-4级:HR 1.86,95%CI 1.27-2.72,p=0.001),但与OS无显著相关(1/2级:HR 1.35,95%CI 0.97-1.88,p=0.08;3/4级:HR 1.53,95%CI 1.00-2.34,p=0.05);残留病灶(p<0.05)和新辅助化疗(p<0.001)与更差PFS和OS相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE(S): To determine whether antibiotic treatment (ABX) during platinum chemotherapy (PC) for epithelial ovarian cancer (EOC) impacts progression-free survival (PFS) and overall survival (OS). STUDY DESIGN: Retrospective single institution cohort study in women with newly diagnosed stage III/IV EOC (n = 424) who underwent cytoreductive surgery (CRS) and PC from 2009 to 2015. ABX for >48 h, including ABX against gram-positive (anti-G + ABX) bacteria were recorded. The impact of ABX on PFS and OS was assessed using univariate and multivariable Cox regression models. RESULTS: Of 424 eligible women, 34.7% (n = 147) received ABX, with 11.3% (n = 48) treated with anti-G + ABX. ABX decreased PFS (17.4 vs. 23.1 months, HR 1.50, 95% CI 1.20-1.88, p < 0.001) and OS (45.6 vs. 62.4 months, HR 1.63, 95% CI 1.27-2.08, p < 0.001) compared to no ABX. Similarly, anti-G + ABX worsened PFS (16.5 vs. 23.1 months; HR 1.85, 95% CI 1.33-2.55) and OS (35.0 vs. 62.4 months; HR 2.12, 95% CI 1.50-3.0, p < 0.001). On multivariable analysis, all ABX and anti-G + ABX significantly worsened PFS (HR 1.31, 95% CI 1.04-1.65, p = 0.02), (HR 1.50, 95% CI 1.07-2.10, p = 0.02) and OS (HR 1.52, 95% CI 1.18-1.96, p = 0.001), (HR 1.83, 95% CI 1.27-2.62, p = 0.001) respectively. Increased Clavien Dindo score was associated with worsened PFS (1-2 - HR 1.52, 95% CI 1.14-2.03, p = 0.004; 3-4 - HR 1.86, 95% CI 1.27-2.72, p = 0.001) but not OS (1/2 - HR 1.35, 95% CI 0.97-1.88, p = 0.08; 3/4 - HR 1.53, 95% CI 1.00-2.34, p = 0.05); residual disease (p < 0.05) and neoadjuvant chemotherapy (p < 0.001) were associated with worse PFS and OS. CONCLUSION(S): In this retrospective cohort study of women with advanced EOC undergoing PC, ABX treatment was associated with decreased PFS and OS. Mechanistic studies are needed to investigate the negative impact of ABX upon PC response in EOC.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Chambers LM, Kuznicki M, Yao M, et al. Impact of antibiotic treatment during platinum chemotherapy on survival and recurrence in women with advanced epithelial ovarian cancer. Gynecol Oncol. 2020. PMID: 32950250. doi:10.1016/j.ygyno.2020.09.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。